Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04043897 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 15, 2021 (before its estimated December 2021 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Apr 2020 to Dec 2021
    • Study completion date: May 2020 to Dec 2021
    • Site contact updated
    v3
  2. Site contact updatedv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.
Trial Details
NCT Number NCT04043897
Lead Sponsor Eugene F Yen, MD
Conditions
(from sponsor)		 Microscopic Colitis
Related terms Colitis, Microscopic
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov